E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy volunteers (Meningitis B) |
Volontari Sani (Meningite B) |
|
E.1.1.1 | Medical condition in easily understood language |
Type B meningitis |
Meningite di tipo B |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10027249 |
E.1.2 | Term | Meningitis meningococcal |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To descriptively assess the safety of Novartis rMenB+OMV NZ in healthy at-risk adults when administered at a 0, 2- month schedule, throughout the clinical study. |
valutare la sicurezza del vaccino Novartis rmenB+OMV NZ in soggetti sani adulti a rischio con schedula di somministrazione 0-2 mesi |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. 18 – 60 years of age inclusive who have given written informed consent at the time of enrollment; 2. Able to comprehend and follow all required study procedures; 3. Who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period); 4. In good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator; 5. Who were or might be routinely exposed to N. meningitidis cultures and/or are travelling to geographical areas considered at high risk for epidemic Meningococcal B infection disease. |
1. soggetti ambosesso tra i 18 e i 60 anni inclusi che abbiano dato il consenso informato scritto al momento dell'arruolamento; 2:Capaci di comprendere e seguire le procedure di studio; 3.Disponibili per tutte le visite di studio (che non abbiano intenzione di trasferirsi prima della fine dello studio); 4. in buona salute come confermato da anamnesi,esame medico e giudizio clinico dello sperimentatore; 5.Che sono stati o che potrebbero essere esposti a colture cellulari di N.Meningitidis e/o viaggiano in aree geografiche considerate ad alto rischio epidemico per infezioni da Meningococco B |
|
E.4 | Principal exclusion criteria |
1.Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥ 38°C|100.4ºF) within the previous day; 2.Antibiotics within 3 days (72 hours) prior to enrollment; 3. Pregnancy or nursing (breastfeeding) mothers; 4. Females who have not used or do not plan to use acceptable birth control measures, for the 3 months duration of the study. Oral, injected or implanted hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry; 5.Any serious chronic or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition); 6.Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, including use of corticosteroids in immunosuppressive doses or chronic use of inhaled high-potency corticosteroids within the previous 60 days. [Use of topical corticosteroids administered during the study in limited areas (i.e., eczema on knees or face or elbows) of the body is allowed]; immunostimulants; 7.History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component; 8.Any condition which in the opinion of the investigator may interfere with evaluation of the study objectives. |
1.Infezioni rilevanti acute o croniche nei precedenti 7 giorni o febbre (definita come temperatura ascellare≥38°C|100.4ºF) il giorno precedente; 2.Assunzione di antibiotici nei 3 giorni (72ore) precedenti l'arruolamento; 3.Donne incinte o in fase di allattamento; 4.Donne che non hanno usato o che non pianificano di usare metodi contraccettivi accettabili per i 3 mesi della durata dello studio.Contraccettivi orali,ormonali iniettabili o impiantabili,diaframma,preservativo,dispositivi intrauterini o l'astinenza sessuale sono considerati metodi contraccettivi accettabili.Se sessualmente attivo il soggetto deve aver usato uno di questi metodi contraccettivi accettati per almeno 30 giorni prima l'entrata in studio. 5.Qualsiasi malattia seria,cronica o progressiva (es.neoplasie,diabete,malattie cardiache,malattie epatiche,malattie neurologiche progressive o disturbi epilettici,malattie autoimmuni,infezioni da HIV o AIDS,discrasia o diatesi del sangue,sintomi di deficienza cardiaca o renale o malnutrizione importante); 6.confermato o sospetto deterioramento/alterazione del sistema immunitario,terapie immunosoppressive incluso l'uso di corticosteroidi in dosi immunosoppressive o uso inalatorio cronico di corticosterodi ad alta potenza nei precedenti 60 giorni[l'uso di corticosterodi in aree limitate del corpo (ad esempio eczema alle ginocchia o al viso o ai gomiti)è permesso;uso di immunostimolanti; 7.Trascorso di serie reazioni allergiche a precedenti vaccinazioni o ipersensibilità ad ogni componente del vaccino; 8.Qualsiasi condizione che in opinione dello sperimentatore possa interferire con la valutazione degli obiettivi dello studio |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
To descriptively assess the safety of Novartis rMenB+OMV NZ in healthy at-risk adults when administ |
Valutare in termini descrittivi la sicurezza del vaccino rMenB+OMV NZ di Novartis in soggetti adulti |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 15 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 15 |
E.8.9.2 | In all countries concerned by the trial days | 0 |